Biswas Asish, Chatterjee Suparna, Chowdhury Rama, Sen Sangita, Sarkar Dipak, Chatterjee Mitali, Das Jayasree
Department of Pharmacology, NRS Medical College, 138 Acharya JC Bose Road, Sealdah Entally, Kolkata-700 014, India.
Acta Pol Pharm. 2012 Sep-Oct;69(5):939-43.
The antidiabetic effect of seeds of Strychnos potatorum Linn. was evaluated in a model of diabetes mellitus using streptozotocin (40 mg/kg b.w., i.p.). Changes in fasting blood sugar were estimated periodically for 12 weeks along with weekly measurement of body weight, food and water intake for 4 weeks. The antidiabetic effects were compared with glipizide as the reference hypoglycemic drug. Strychnos potatorum Linn. (100 mg/kg p.o.) significantly reduced fasting blood sugar, the effects being comparable with glipizide (40 mg/kg, p.o.), an established hypoglycemic drug. It also increased body weight along with decreased food and water intake in streptozotocin-induced diabetic rats. Taken together, Strychnos potatorum Linn. shows promise as an effective hypoglycemic compound worthy of future pharmacological investigations.
在使用链脲佐菌素(40毫克/千克体重,腹腔注射)建立的糖尿病模型中,对马钱子(Strychnos potatorum Linn.)种子的抗糖尿病作用进行了评估。在12周内定期估计空腹血糖的变化,并在4周内每周测量体重、食物和水的摄入量。将抗糖尿病作用与作为参考降糖药物的格列吡嗪进行比较。马钱子(100毫克/千克,口服)显著降低了空腹血糖,其效果与已确立的降糖药物格列吡嗪(40毫克/千克,口服)相当。它还增加了链脲佐菌素诱导的糖尿病大鼠的体重,同时减少了食物和水的摄入量。综上所述,马钱子有望成为一种有效的降糖化合物,值得未来进行药理学研究。